| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 09.02.
| Sangamo BioSciences Announces Presentation at 2012 Leerink Swann Global Healthcare Conference | | 19 | PR Newswire |
| RICHMOND, Calif., Feb. 9, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the...
Mehr lesen zu:
Sangamo BioSciences Announces Presentation at 2012 Leerink Swann Global Healthcare Conference | |
| 09.02.
| Sangamo BioSciences' CEO Discusses Q4 2011 Results - Earnings Call Transcript | | 25 | Seeking Alpha |
| 08.02.
| Sangamo BioSciences Reports Fourth Quarter and Full Year 2011 Financial Results | | 28 | PR Newswire |
| RICHMOND, Calif., Feb. 8, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported fourth quarter and full year 2011 financial results and accomplishments.
For the fourth quarter...
Mehr lesen zu:
Sangamo BioSciences Reports Fourth Quarter and Full Year 2011 Financial Results | |
| 07.02.
| Shire and Sangamo Cut a Deal | | 24 | Zacks |
| 02.02.
| Shire partners Sangamo to develop hemophilia treatments | | 58 | Pharma Bus Review |
| 01.02.
| Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast | | 92 | PR Newswire |
| RICHMOND, Calif., Feb. 1, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its fourth quarter and full year 2011 financial results on Wednesday...
Mehr lesen zu:
Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast | |
| 01.02.
| Sangamo soars 26% on Shire deal | | 38 | MarketWatch |
| 01.02.
| Hot Stock: Sangamo Biosciences, Shares Gain 5.5% | | 31 | SmarTrend |
| 01.02.
| Sangamo (SGMO) Shares Rise Amid Deal with Shire (SHPGY) to Develop Therapeutics Treatment for Hemophilia | | 34 | StreetInsider.com |
| 01.02.
| Shire, Sangamo Team To Develop Therapeutics For Hemophilia, Monogenic Diseases | | 78 | AFX News |
| SAINT HELIER (dpa-AFX) - Sangamo BioSciences, Inc. (SGMO) announced that it
entered into a collaboration and license agreement with Shire plc (SHP.L, SHPGY)
to develop therapeutics for hemophilia...
Mehr lesen zu:
Shire, Sangamo Team To Develop Therapeutics For Hemophilia, Monogenic Diseases | |
| 01.02.
| Shire and Sangamo Collaborate to Develop Therapeutics for the Treatment of Hemophilia and Other Monogenic Diseases | | 136 | PR Newswire |
| DUBLINand RICHMOND, Calif., Feb. 1, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, and Sangamo BioSciences, Inc. (NASDAQ: SGMO)...
Mehr lesen zu:
Shire and Sangamo Collaborate to Develop Therapeutics for the Treatment of Hemophilia and Other Monogenic Diseases | |
| 12.01.
| Sangamo BioSciences' CEO Presents at the 30th Annual J.P. Morgan Healthcare Conference (Transcript) | | 77 | Seeking Alpha |
| 09.01.
| Sangamo (SGMO) Initiates Two ZFP Therapeutic Phase IIs | | 54 | StreetInsider.com |
| 09.01.
| Sangamo BioSciences Announces Initiation of Two New Phase 2 HIV Clinical Trials | | 149 | PR Newswire |
| RICHMOND, Calif., Jan. 9, 2012 /PRNewswire/ --Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the initiation of two new Phase 2 clinical studies (SB-728-1101 and SB-728-902, Cohort 5) in...
Mehr lesen zu:
Sangamo BioSciences Announces Initiation of Two New Phase 2 HIV Clinical Trials | |
| 05.01.
| Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference | | 71 | PR Newswire |
| RICHMOND, Calif., Jan. 5, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on...
Mehr lesen zu:
Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference | |
| 13.12.
| Sangamo BioSciences (SGMO) Presents New Data from ZFP Therapeutic Program at American Society for Hematology Meeting | | 55 | StreetInsider.com |
| 13.12.
| Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting | | 32 | PR Newswire |
| RICHMOND, Calif., Dec.13, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating the ability to permanently correct...
Mehr lesen zu:
Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting | |
| 08.11.
| Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference | | 53 | PR Newswire |
| RICHMOND, Calif., Nov. 8, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of...
Mehr lesen zu:
Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference | |
| 04.11.
| SANGAMO BIOSCIENCES INC - 10-Q, Quarterly Report | | 23 | SEC Filings |
| 25.10.
| Sangamo BioSciences Reports Third Quarter 2011 Financial Results | | 63 | PR Newswire |
| RICHMOND, Calif., Oct. 25, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported third quarter 2011 financial results and accomplishments.
For the third quarter ended September...
Mehr lesen zu:
Sangamo BioSciences Reports Third Quarter 2011 Financial Results | |
